NEW YORK, Oct. 7, 2016 /PRNewswire/ -- Nadeem Faruqi,
founding partner at Faruqi & Faruqi, LLP, a leading national
securities firm headquartered in New York
City, is investigating the Board of Directors of EndoChoice
Holdings, Inc. ("EndoChoice" or the "Company") (NYSE:GI) for
potential breaches of fiduciary duties in connection with the sale
of the Company to Boston Scientific Corporation for approximately
$195.46 million.
The Company's stockholders will only receive $8.00 in cash for each share of Company common
stock they own. However, this consideration is below at least one
analyst's price target of $10.00 per
share and EndoChoice's 52-week high of $12.44 per share.
Click here for more information:
www.faruqilaw.com/GI. There is no cost or obligation to
you.
The investigation focuses on whether EndoChoice's Board of
Directors breached their fiduciary duties to the Company's
stockholders by failing to conduct a fair sales process and whether
and by how much this proposed transaction undervalues the Company
to the detriment of EndoChoice's shareholders.
Faruqi & Faruqi, LLP is a national law firm which represents
investors and individuals in class action litigation. The firm
is focused on providing exemplary legal services in complex
litigation in the areas of securities, shareholder, antitrust and
consumer litigation, throughout all phases of litigation. The
firm has an experienced trial team which has achieved significant
victories on behalf of the firm's clients. To keep track of the
latest securities litigation news, follow us on Twitter at
www.twitter.com/MergerActivity or on Facebook at
www.facebook.com/FaruqiLaw.
Faruqi & Faruqi, LLP is working together in this
investigation with Juan E.
Monteverde from Monteverde & Associates PC.
If you own common stock in EndoChoice and wish to obtain
additional information and protect your investments free of charge,
please visit us at www.faruqilaw.com/GI or contact Nadeem Faruqi, Esq. either via e-mail at
nfaruqi@faruqilaw.com or by telephone at (877) 247-4292 or (212)
983-9330. You may also contact Juan E. Monteverde,
Esq. either via email at jmonteverde@monteverdelaw.com or by
telephone at (212) 971-1341.
Contact:
Faruqi & Faruqi, LLP
685 Third Avenue, 26th Floor
New York, NY 10017
Attn: Nadeem Faruqi, Esq.
nfaruqi@faruqilaw.com
Toll Free: (877) 247-4292
Phone: (212) 983-9330
Attorney Advertising. (C) 2016 Faruqi & Faruqi, LLP. The law
firm responsible for this advertisement is Faruqi & Faruqi, LLP
(www.faruqilaw.com). Prior results do not guarantee or predict
a similar outcome with respect to any future matter. We are
happy to discuss your particular case.
Logo -
http://photos.prnewswire.com/prnh/20120119/MM38856LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/endochoice-shareholder-notice-faruqi--faruqi-llp-announces-the-investigation-of-endochoice-holdings-inc-gi-over-the-proposed-sale-of-the-company-to-boston-scientific-corporation-300341456.html
SOURCE Faruqi & Faruqi, LLP
